Share Success: Letters From Readers
I: From Rob G
Submit Form Thursday, July 02, 2015 at 10:20:09
Hi, my name is Rob G I'm 54.
Marvlix I found out has dual properties. First I started taking it for my Asthma, now what it has done after one month is increase my lung capacity and ability to work out in the gym, but I still take my Singulair tablets for maintenance and keep my Ventolin inhaler on standby always. What I find is that Marvlix increases the effectiveness of my asthma medication not replace it.
What Marvlix does do is dropped my BP to 120 /70 ,which my doctor said he had not seen my BP at such a fantastic level ever. I just re-ordered my next 3 bottles I will see
how the second month goes. I take 6 tablets a day as prescribed.
II: From Cathy
Submit Form Thursday, April 30, 2015 at 08:27:57
Hi, my name is Cathy. I have been having problems with my heart since I was a child. It would race periodically throughout my life.
When I was 58 yrs old, I had heart surgery. I thought it would correct the problem I had as a child & adult. Be it didn't.
Just recently my older sister passed away. She was diagnosed with ALS. Like my younger sister died from many years ago. Drs. that knew of our association with familiar ALS told us that we should start taking certain herbs. That would help us. One of the herbs was the Ezorb Calcium.
I ordered and when I received it, it had brochures about another product Marvlix. I read about it and purchased it with the Calcium.
I have been taking now for at least 6 months. I have noticed that the Marvlix regulated my heart and I do not experience my racing anymore. I will take Marvlix faithfully for the rest of my life. I tell everyone I see about Marvlix and Ezorb Calcium.
Ezorb Calcium has improved my knee that I injured many years ago. I don't have any trouble going up or down stairs. Thank you Ezorb for making 2 products, that I will take for the rest of my life and I will continue to tell people of the benefits of these 2 products.
God Bless Ezorb.
Cathy : Breaux Bridge, Louisiana
III: From Thomas P.
Saturday, May 9, 2015 9:15 AM
Hi, my name is Thomas Premo. I provided feedback before on my excellent success with EZorb. I was not sure if I needed the full 6 capsules of 3 servings a day. To find out, I stopped taking EZorb to see how long I would remain pain free.
Answer: only a few weeks. The discomfort in my shoulder due to a bone spur came back then with a vengeance all in one day. I resumed EZorb at half my previous dosage -- 3 capsules a day -- one taken with each meal. Comfort and strength returned in just a few days. What a wonderful product!
Monday, April 13, 2015 1:43 PM
Hi, my name is Thomas Premo ... meant to include that I tried several glucosamine formulations all of which had no effect at all. EZorb rocks!
the Desk of EZorb Newsletter Editor:
newsletter is now read by over 70,000 subscribers
worldwide. Success stories you have contributed over
the years have had a great impact on many people's
quality of life. Your continuous support will be
greatly appreciated by tens of thousands who have been
suffering and would continuously suffer, without your
help! Please email your
story to sharesuccess @ ezorbonline.com
or simply post it at Testimonial
Submit Form. Your personal information will never be
revealed to the public. If your testimonial is selected for publication, you will receive a free gift of 3 bottles of EZorb Capsules, EZorb Powder, or Marvlix of your choice.
Research News: Medication in Need for Neuropathic Pain
A systematic review and meta-analysis reveals that current treatments for neuropathic pain achieve only a moderate response in patients.
Nadine Attal (Hospital Ambroise Pare, Paris, France) and study co-authors included 196 published papers in their analysis, as well as 33 unpublished studies identified in clinical trial registries.
Based on Grading of Recommendations Assessment, Development, and Evaluation (GRADE) recommendations, the team says there is strong evidence for first-line use of tricyclic antidepressants, serotonin-noradrenaline reuptake inhibitors (duloxetine or venlafaxine), pregabalin and gabapentin in patients with neuropathic pain.
For these medications, the average number needed to treat (NNT) to obtain a 50% reduction in pain ranged from 3.6 for tricyclic antidepressants to 7.7 for pregabalin. The quality of evidence was high for most treatments, with the exception of tricyclic antidepressants, for which it was moderate.
However, further analysis indicated publication bias, suggesting about 34 missing studies and a 10% overstatement of the treatment effect. Likewise, the treatment effects found in published studies were significantly greater than those found in unpublished studies. But the effect of the putative missing studies did not risk negating the treatment effect, except in the case of capsaicin 8% patches, in which the NNT would have increased to more than 11, and therefore become clinically nonsignificant, if a missing study was negative.
"This finding lends support to the robustness of a meta-analysis that includes unpublished trials and suggests that effect sizes were overestimated in previous meta-analyses of pharmacotherapy for neuropathic pain", write Attal et al in The Lancet Neurology.
Capsaicin 8% patches therefore had a weak GRADE recommendation, as did lidocaine patches, tramadol, botulinum toxin A and strong opioids due to poor evidence, high expense or safety concerns.
Four drugs had weak (cannabinoids, valproate) or strong (levetiracetam, mexiletine) recommendations against use because of negative trials or side effects, and a further 12 therapies had inconclusive recommendations.
Treatments with inconclusive evidence included combination therapy, a point picked up on by David Bennett (University of Oxford, UK) in a linked commentary, saying that although combining treatments is "intellectually appealing", studies to date have been mostly small, with the only large study so far being negative.
"Because so many patients in clinical practice are on more than one analgesic, more studies are needed in this area", he says. "Overall, present options are far from ideal and new and more efficacious treatments than exist at present are needed for neuropathic pain."
Original research was published in Lancet Neurol 2015; 14: 162–173.
Asked Questions & Answers
Calcium has set a new world record of absorption rate.
You can compare EZorb with other calcium supplements
by using the simple step-by-step instructions we
provide. E-mail your request to test @ elixirindustry.com
for a copy of the instructions.
What Are Others Saying About EZorb and Marvlix?
EZorb and Marvlix have restored confidence in thousands of men
and women. It has brought happiness and healthy life
to families around the world. Click here
to read what people say about EZorb and Marvlix.